Breaking News

Biothera Names Biomarker Development VP

By Kristin Brooks | January 28, 2014

Maimonis to lead development and commercialization of assays for Phase III cancer drug

Peter J. Maimonis, Ph.D. has been appointed vice president of biomarker development at Biothera and will lead the development and commercialization of assays for the company’s Phase III cancer immunotherapy, Imprime PGG. Dr. Maimonis previously held senior positions with various pharmaceutical and diagnostic companies, including senior director, Cancer Cell Biology at On-Q-ity, vice president of Biology R&D at Decision Biomarkers, and associate director for Oncology Research at Bayer Health Care.
 
“For the past quarter century Dr. Maimonis has focused on the discovery and development of oncology biomarkers, companion diagnostics and assays,” said Dan Conners, president of Biothera’s Pharmaceutical Group. “His expertise is a perfect fit for Biothera as we advance the science of the predictive biomarker for Imprime PGG.”

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity